Search Results
Your search for all items matches 35617 pages
Showing 26101 - 26150
Bridgett Harr, CNP, on Reducing ER Visits and Admissions in High-Risk Head and Neck Cancer Patients
Bridgett Harr, CNP, of Cleveland Clinic, discusses the advanced practice nurse follow-up clinic, which focuses on symptom management in the first 90 days postchemoradiation (Abstract 3169).
Vratislav Strnad, MD, PhD, on Multicatheter Brachytherapy After Breast-Conserving Surgery
Vratislav Strnad, MD, PhD, of the University Hospital in Erlangen, discusses results from a European study comparing accelerated partial-breast irradiation using brachytherapy, to the standard treatment of whole-breast irradiation for women with low-risk breast cancer (Abstract LBA7).
Jay Harris, MD, on Making Sense of Conflicting Data on Breast Irradiation
Jay Harris, MD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, discusses the difficulty reconciling recent important trials on radiotherapy for breast cancer: The Z11 trial suggested that breast tangents are sufficient, while MA.20 and EORTC studies suggested that full nodal...
Christopher Brian Allard, MD, on Prostate Cancer Risk and Regular Aspirin Use
Christopher Brian Allard, MD, of Brigham & Women's Hospital, reports on results of the Physicians’ Health Study, which showed that regular aspirin use decreased the risk of lethal prostate cancer in a cohort of American doctors (Abstract 306).
Christopher J. Sweeney, MBBS: Testicular Cancer Update
Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, reviews important presentations on testicular cancer, including dose intensification for first-line therapy of metastatic disease, and what physicians need to know about the molecular genetics of testicular cancer.
Maha Hussain, MD, on Prostate Cancer: Keynote Lecture
Maha Hussain, MD, of the University of Michigan, gives her expert perspective on changes in the treatment of hormone-naive disease.
W. Robert Lee, MD, on Prostate Cancer: Results of the NRG Oncology RTOG 0415 Study
W. Robert Lee, MD, of Duke University, discusses this phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer (Abstract 1).
Nicholas D. James, BSc, MBBS, PhD, on Urothelial Carcinomas: Year in Review
Nicholas D. James, BSc, MBBS, PhD, of the University of Warwick, gives his expert perspective on treatment advances in urothelial cancers.
Paul L. Nguyen, MD, on Prostate Cancer: Results of the NRG Oncology/RTOG 9601 Study
Paul L. Nguyen, MD, of Dana-Farber Cancer Institute, discusses this phase III trial in which prostate cancer patients were given antiandrogen therapy with bicalutamide during and after salvage radiation therapy following radical prostatectomy and an elevated PSA (Abstract 3).
Srikala S. Sridhar, MD: Bladder Cancer Update
Srikala S. Sridhar, MD, of the Princess Margaret Cancer Centre, summarizes important papers presented on bladder and urothelial cancers, including perspectives on immunotherapies and radiotherapies.
Fred Saad, MD, on Prostate Cancer: The Year in Review (French Language Version) 
Fred Saad, MD, of the University of Montreal, summarizes in French his session on the latest treatment developments in prostate cancer, including the role of chemotherapy in hormone-sensitive disease.
Fred Saad, MD, on Prostate Cancer: The Year in Review
Fred Saad, MD, of the University of Montreal, summarizes his session on the latest treatment developments in prostate cancer, including the role of chemotherapy in hormone-sensitive disease. To see the French language version of this video, click here.
Toni Choueiri, MD: Renal Cancer Update
Toni Choueiri, MD, of the Dana-Farber Cancer Institute, summarizes key points from a session he chaired on clear and non-clear cell renal cancer, including information on molecular genetics and its impact on treatment, how to treat patients with non-clear cell histology, and the best strategy for...
Hans-Joerg Hammers, MD, PhD, on Renal Cancer: Using Immune Checkpoint Blockers in the Clinic
Hans-Joerg Hammers, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, summarizes this keynote lecture on kidney cancer, which included discussion of the current role of PD-1 monotherapy and future PD-1 combination therapies for renal cell carcinoma.
Bishoy M. Faltas, MD, on Advanced Urothelial Carcinoma: Generating a Neoantigen Map
Bishoy M. Faltas, MD, of Weill Cornell Medical College, discusses his team’s work using whole exome sequencing, which may have important implications for selecting patients for immunotherapeutic approaches (Abstract 354).
Dean F. Bajorin, MD, on Rare Urinary Tract Cancers: Expert Perspectives on Treatment
Dean F. Bajorin, MD, of Memorial Sloan Kettering Cancer Center, summarizes a panel discussion on this important topic.
David P. Dearnaley, MD, on Prostate Cancer: Results from the CHHiP Trial
David P. Dearnaley, MD, of The Royal Marsden NHS Foundation Trust, discusses the comparison, in this study, of hypofractionated high-dose IMRT schedules for prostate cancer (Abstract 2).
Bernard J. Escudier, MD, on Renal Cell Carcinoma: Results From the METEOR Trial (French Language Version)
Bernard J. Escudier, MD, of the Institut Gustave Roussy, discusses in French a subgroup analyses of this phase III study of cabozantinib vs everolimus in patients with advanced renal cell carcinoma (Abstract 499).
Bernard J. Escudier, MD, on Renal Cell Carcinoma: Results From the METEOR Trial
Bernard J. Escudier, MD, of the Institut Gustave Roussy, discusses a subgroup analyses of this phase III study of cabozantinib vs everolimus in patients with advanced renal cell carcinoma (Abstract 499). To see the French language version of this video, click here.
Matthew Smith, MD, PhD, on Bone Metastases: Treatment Update
Matthew Smith, MD, PhD, of the Massachusetts General Hospital Cancer Center, discusses the best use of approved therapies for tumors that have spread to the bone.
Craig E. Pollack, MD, on Low-Income Breast Cancer Survivors: Clinical Trial Results
Craig E. Pollack, MD, of Johns Hopkins University, discusses a study of survivorship care plans for this special population (Abstract 1).
Jennifer A. Ligibel, MD, on Breast Cancer Survivorship in Young Women
Jennifer A. Ligibel, MD, of the Dana-Farber Cancer Institute, discusses the physical activity behaviors and weight changes in a study cohort of young women with breast cancer (Abstract 166).
Lewis E. Foxhall, MD, on Communication and Coordination of Survivorship Care
Lewis E. Foxhall, MD, of The University of Texas MD Anderson Cancer Center, summarizes this session in which presenters covered a range of issues, including the medical home, tools to facilitate communication with cancer survivors, EMRs, reimbursement, and coordinating care with primary care...
Smita Bhatia, MD, MPH, on the Science of Survivorship
Smita Bhatia, MD, MPH, of the University of Alabama at Birmingham, discusses long-term and late effects experienced by cancer survivors.
Kevin C. Oeffinger, MD, on Highlights of the ASCO Survivorship Symposium
Kevin C. Oeffinger, MD, of Memorial Sloan Kettering Cancer Center, summarizes the main take-home messages of the conference.
Christopher J. Recklitis, PhD, MPH, on Fatigue and Sleep Disturbances
Christopher J. Recklitis, PhD, MPH, of Dana-Farber Cancer Institute, discusses these side effects and some practical approaches to managing them with educational, medical, behavioral, and lifestyle interventions.
Dana Barnea, MD, on Screening Survivors for Thyroid Cancer
Dana Barnea, MD, of Memorial Sloan Kettering Cancer Center, discusses data that suggest annual palpation of the thyroid is an adequate and safe means of screening childhood and young adult cancer survivors, a population at high risk for this type of cancer (Abstract 254).
Mary S. McCabe, RN, on Risk-Based Health Care of Cancer Survivors
Mary McCabe, RN, of Memorial Sloan Kettering Cancer Center, discusses various models of delivering survivorship care.
Tara O. Henderson, MD, MPH, on Cancer Survivors With Complex Medical Needs
Tara O. Henderson, MD, MPH, of the University of Chicago, summarizes a session on the multidisciplinary approaches to survivors with medical needs beyond cancer treatment.
Erin Elizabeth Hahn, PhD, MPH, on Hodgkin Lymphoma: Post-Treatment Services
Erin Elizabeth Hahn, PhD, MPH, of Kaiser Permanente Southern California, discusses the use of recommended post-treatment services for adolescent and young adult Hodgkin lymphoma survivors (Abstract 107).
Rachel Lynn Yung, MD, on Weight-Loss Intervention in Obese Survivors
Rachel Lynn Yung, MD, of the Dana-Farber Cancer Institute, discusses her study of a clinic-based intervention for overweight cancer survivors, which resulted in weight loss and improvements in fitness and physical functioning (Abstract 167).
Kerri M. Winters-Stone, PhD, on Peripheral Neuropathy: High Prevalence Among Female Survivors
Kerri M. Winters-Stone, PhD, of Oregon Health and Science University, discusses the results of her study, which showed that, years after treatment, nearly half of women cancer survivors still have symptoms of chemotherapy-induced peripheral neuropathy. The findings may inform rehabilitative...
Tim A. Ahles, PhD, on Neurocognitive Late Effects
Tim A. Ahles, PhD, of Memorial Sloan Kettering Cancer Center, discusses “chemobrain” and what can be done to help patients cope with this symptom.
Heinz-Josef Lenz, MD, on Metastatic Colorectal Cancer: Results of the MAVERICC Study (German Language Version) 
Heinz-Josef Lenz, MD, of the USC Norris Comprehensive Cancer Center, discusses in German the findings of this phase II study of mFOLFOX6/bevacizumab vs FOLFIRI/bevacizumab with biomarker stratification in patients with metastatic colorectal cancer (Abstract 493).
Heinz-Josef Lenz, MD, on Metastatic Colorectal Cancer: Results of the MAVERICC Study
Heinz-Josef Lenz, MD, of the USC Norris Comprehensive Cancer Center, discusses the findings of this phase II study of mFOLFOX6/bevacizumab vs FOLFIRI/bevacizumab with biomarker stratification in patients with metastatic colorectal cancer (Abstract 493). To view the German language version of this...
Dung T. Le, MD, on Gastric or Gastroesophageal Junction Cancer: Results From the CheckMate-032 Trial
Dung T. Le, MD, from Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, discusses study findings on the safety and activity of nivolumab monotherapy in advanced and metastatic gastric or gastroesophageal junction cancer (Abstract 6).
Jonathan R. Strosberg, MD, on Neuroendocrine Tumors: Results of the NETTER-1 Trial
Jonathan R. Strosberg, MD, of H. Lee Moffitt Cancer Center and Research Institute, discusses progression-free survival, radiographic response, and preliminary overall survival findings of this phase III study on midgut neuroendocrine tumors treated with lutetium Lu-177 dotatate (Abstract 194).
Yoon-Koo Kang, MD, PhD, on Gastric/Gastroesophageal Junction Adenocarcinoma: Trial Results for T-DM1 vs a Taxane
Yoon-Koo Kang, MD, PhD, of the Asan Medical Center, discusses findings from this multicenter, phase II/III study of ado-trastuzumab emtansine vs a taxane in patients with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (Abstract 5).
Simron Singh, MD, on Neuroendocrine Tumors of the GI Tract: Results from the RADIANT-4 Trial
Simron Singh, MD, of the Toronto Sunnybrook Cancer Centre, discusses an analysis of data from this phase III study on the efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors of the GI tract and unknown primary (Abstract 315).
Somnath Mukherjee, MD, on Esophageal Adenocarcinoma: Results of the NEOSCOPE Trial
Somnath Mukherjee, MD, of Oxford University, discusses this phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine- or paclitaxel/carboplatin-based chemoradiation as a pre-operative regimen for resectable esophageal cancer.. (Abstract 3).
Krzysztof Bujko, MD, on Rectal Cancer: Results of a Phase III Trial
Krzysztof Bujko, MD, of the Maria Skłodowska Curie Memorial Cancer Centre, discusses the results of a multicenter Polish study on neoadjuvant chemoradiation for fixed cT3 or cT4 rectal cancer (Abstract 489).
Daniel G. Haller, MD, on Colon and Rectal Cancers: A Global Overview
Daniel G. Haller, MD, of the Abramson Cancer Center, discusses emerging global approaches to these diseases, emphasizing the studies that allow physicians to individualize treatments.
Toshihiko Doi, MD, PhD, on Esophageal Carcinoma: Study Results From KEYNOTE-028
Toshihiko Doi, MD, PhD, of Japan’s National Cancer Center Hospital East, discusses updated results on pembrolizumab for advanced esophageal cancer (Abstract 7).
Richard S. Finn, MD, on Advanced Hepatocellular Carcinoma: Expert Perspective
Richard S. Finn, MD, of the University of California Los Angeles Medical Center, summarizes a session on treatments for advanced hepatocellular carcinoma (Abstract 192).
Dung T. Le, MD, on Noncolorectal GI Cancers: Results From a Phase II Study of Pembrolizumab
Dung T. Le, MD, from Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, reports findings on this agent, which showed promising activity in patients with previously treated progressive, advanced cancer (Abstract 195).
Eric Francois, MD, on Rectal Cancer: Findings From the ACCORD12 Trial (French Language Version)
Eric Francois, MD, of the Centre Antoine-Lacassagne, discusses in French the 5-year follow-up results from this phase III study of neoadjuvant treatment in rectal cancer (Abstract 490).
Eric Francois, MD, on Rectal Cancer: Findings From the ACCORD12 Trial
Eric Francois, MD, of the Centre Antoine-Lacassagne, discusses the 5-year follow-up results from this phase III study of neoadjuvant treatment in rectal cancer (Abstract 490). To view the French language version of this newsreel, click here.
Patricia A. Ganz, MD, on Looking Beyond the Scans: What to Look For and How
Patricia A. Ganz, MD, of the University of California at Los Angeles, discusses the limited sensitivity and specificity of surveillance testing for cancer recurrence and finding a better way to reassure patients about their continuing care.
A. Oliver Sartor, MD, on Advanced Prostate Cancer: Predicting Treatment Resistance
A. Oliver Sartor, MD, of Tulane Cancer Center, discusses this study investigating circulating tumor cell characteristics to predict resistance to androgen deprivation therapies in patients with advanced prostate cancer (Abstract 163).
James L. Abbruzzese, MD, on Pancreatic Cancer: Expert Perspective
James L. Abbruzzese, MD, of Duke University, discusses the international outlook on patterns of care and their impact on outcomes.
